Frontline Bostunib vs Imatinib in Chronic Myeloid Leukemia

CAR T and Transplantation Advances Across Hematologic Cancers at ASCO 2025

Researchers have found that donor age is a key determinant of outcomes in hematopoietic cell transplantation, with younger donors associated with significantly better survival and lower rates of GVHD.

An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.

Rahul Banerjee, MD, FACP;Taha Al-Juhaishi, MD;Muhammad Salman Faisal, MD

Generic Ibrutinib Tablets Earn Tentative FDA Approval in Blood Cancers

An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.

Ibrutinib tablets will become available at 140 mg, 280 mg, and 420 mg for patients with chronic lymphocytic leukemia and Waldenstrom macroglobulinemia.

Russ Conroy

Reviewing Real-World Use of Beti-Cel in Transfusion-Dependent β-Thalassemia

Ibrutinib tablets will become available at 140 mg, 280 mg, and 420 mg for patients with chronic lymphocytic leukemia and Waldenström macroglobulinemia.

Therapies like betibeglogene autotemcel have been “life-changing” for patients with β-thalassemia, according to Nora M. Gibson, MD, MSCE.

Nora M. Gibson, MD, MSCE;Taha Al-Juhaishi, MD

Tambiciclib Plus Ven/Aza Met All Primary End Points in R/R AML Trial

Therapies such as betibeglogene autotemcel have been “life-changing” for patients with β-thalassemia, according to Nora M. Gibson, MD, MSCE.

The FDA has asked tambiciclib’s developer to start a trial investigating the combination in front-line acute myeloid leukemia.

Tim Cortese

Developers Resubmit BLA for Tab-Cel in EBV+ Lymphoproliferative Disease

The FDA has asked tambiciclib’s developer to start a trial investigating the combination in front-line acute myeloid leukemia.

The FDA lifted a clinical hold on a new drug application for tabelecleucel as a treatment for EBV-positive lymphoproliferative disease in May 2025.

Roman Fabbricatore

Choosing Between HLA-Mismatched Unrelated and Haploidentical Donors: Donor Age Considerations

The FDA lifted a clinical hold on a new drug application for tabelecleucel as a treatment for EBV-positive lymphoproliferative disease in May 2025.

Related Content

American Society for Transplantation and Cellular Therapy

CAR T and Transplantation Advances Across Hematologic Cancers at ASCO 2025

Rahul Banerjee, MD, FACP;Taha Al-Juhaishi, MD;Muhammad Salman Faisal, MD

Generic Ibrutinib Tablets Earn Tentative FDA Approval in Blood Cancers

An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.

Russ Conroy

Reviewing Real-World Use of Beti-Cel in Transfusion-Dependent β-Thalassemia

Ibrutinib tablets will become available at 140 mg, 280 mg, and 420 mg for patients with chronic lymphocytic leukemia and Waldenström macroglobulinemia.

Nora M. Gibson, MD, MSCE;Taha Al-Juhaishi, MD

Tambiciclib Plus Ven/Aza Met All Primary End Points in R/R AML Trial

Therapies such as betibeglogene autotemcel have been “life-changing” for patients with β-thalassemia, according to Nora M. Gibson, MD, MSCE.

Tim Cortese